New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:26 EDTVRX, OMPIValeant price target raised to $80 from $70 at RBC Capital
RBC Capital increased its price target on Valeant (VRX) to reflect the Obagi (OMPI) acquisition, higher conviction levels for IDP-108 launch and an expected increase to 2013 guidance during the Q1 results conference call. The firm doesn't see the Obagi deal as transformational for Valeant but does expect it to generate at least $40M in synergies. RBC maintains an Outperform rating on Valeant.
News For VRX;OMPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use